Are biotech shares like Polynovo (ASX:PNV) a better buy than Afterpay?

Why I think ASX biotech shares like Polynovo Ltd (ASX: PNV) can outperform even the hottest of tech shares including Afterpay Ltd (ASX: APT).

| More on:
woman in lab coat conducting testing representing biotech

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

ASX tech shares have been rocketing in 2020 thanks to the likes of Afterpay Ltd (ASX: APT). The Afterpay share price has surged 144.9% higher but I think the tide is starting to turn. In my mind, biotech shares like Polynovo Ltd (ASX: PNV) are shaping up as the hot new buys in the market.

Why ASX biotech shares can outperform in 2020

The coronavirus pandemic has thrown a real spanner in the works. Dividends have been slashed, forcing many investors to look for growth instead.

That has seen tech shares like Afterpay continue to surge higher. Software-as-a-service (SaaS) businesses have managed to maintain revenue and keep costs low in 2020.

However, I think ASX biotech shares like Polynovo are looking like the next big thing.

To be clear, the fact that Polynovo has strong growth prospects is not a new idea. The Polynovo share price is up 21.0% this year alone and has a market capitalisation of $1.5 billion.

But COVID-19 has shown that the biotechnology sector has a lot of innovation ahead of it with some seriously strong research and development prospects.

The reason I like Polynovo is because of its strong track record and defined future strategy. The group's NovoSorb BTM product has seen resounding success across the world in the dermal scaffolding market.

Now Polynovo is seeking to reach out even further. At the top of the list are the lucrative hernia and breast augmentation markets which could see Polynovo earnings soar.

It's not just Polynovo that I like amongst the ASX biotech shares. I'm quietly bullish on the Mesoblast limited (ASX: MSB) share price after its recent success with the United States Oncologic Drugs Advisory Committee approving its remestemcel-L treatment for acute graft versus host disease.

Foolish takeaway

There's no doubt that ASX tech shares like Afterpay have outperformed in 2020. However, I think it's worth avoiding the trap of chasing gains that may have already gone and not buying in at the absolute top of the market.

ASX biotech shares could be on the rise with growing addressable markets and a solid track record. That's why I think the Polynovo share price could be good value at $2.25 per share.

Ken Hall has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of POLYNOVO FPO. The Motley Fool Australia owns shares of AFTERPAY T FPO. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

The Mesoblast share price just rocketed 38%! Here's why

ASX investors just sent the Mesoblast share price up 38%. But why?

Read more »

couple having a happy discussion with a banker
Healthcare Shares

Expert: 4 ASX healthcare stocks to buy ahead of reporting season

Could these ASX healthcare stocks be good additions to your portfolio?

Read more »

Excited couple celebrating success while looking at smartphone.
Healthcare Shares

Guess which ASX 200 stock just jumped 9% on big news

Let's find out what is getting investors excited today.

Read more »

Male doctor in a lab coat working at laptop looking serious.
Healthcare Shares

What are Cochlear shares worth according to Macquarie?

Let's see what the broker is saying about this blue chip.

Read more »

Shot of a mature scientists working on a laptop in a lab.
Healthcare Shares

When will CSL shares finally catch a break?

Here's where analysts think the biotech stock is heading next.

Read more »

An analyst wearing a dark blue shirt and glasses sits at his computer with his chin resting on his hands as he looks at the CBA share price movement today
Healthcare Shares

JP Morgan initiates coverage of Telix Pharmaceuticals. After rising 1,667% in 5 years, is it still a buy?

Can this ASX 200 juggernaut go higher?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why this top broker expects CSL shares to surge 26%

A leading broker foresees a big rebound ahead for CSL shares. But why?

Read more »

Man jumps for joy in front of a background of a rising stocks graphic.
Healthcare Shares

Guess which ASX All Ords stock is jumping on big US news

This small cap is catching the eye on Thursday. But why?

Read more »